Cite
HARVARD Citation
Fleischmann, R. et al. (2022). Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial. Lancet. pp. e395-e406. [Online].